These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29314302)

  • 1. Toxic epidermal necrolysis: a review of 20 years of data.
    Marchitto MC; Sung S; Doong J; Chien AL
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e263-e264. PubMed ID: 29314302
    [No Abstract]   [Full Text] [Related]  

  • 2. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention.
    Miliszewski MA; Kirchhof MG; Sikora S; Papp A; Dutz JP
    Am J Med; 2016 Nov; 129(11):1221-1225. PubMed ID: 27086495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience.
    McCullough M; Burg M; Lin E; Peng D; Garner W
    Burns; 2017 Feb; 43(1):200-205. PubMed ID: 27554629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China.
    Yang L; Shou YH; Li F; Zhu XH; Yang YS; Xu JH
    Burns; 2020 Jun; 46(4):959-969. PubMed ID: 31898979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy: Etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Pham CH; Gillenwater TJ; Nagengast E; McCullough MC; Peng DH; Garner WL
    Burns; 2019 Nov; 45(7):1634-1638. PubMed ID: 31466921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results.
    Papp A; Sikora S; Evans M; Song D; Kirchhof M; Miliszewski M; Dutz J
    Burns; 2018 Jun; 44(4):807-815. PubMed ID: 29627131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allopurinol-Induced Stevens-Johnson Syndrome.
    Gupta SS; Sabharwal N; Patti R; Kupfer Y
    Am J Med Sci; 2019 Apr; 357(4):348-351. PubMed ID: 30638600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrence of Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol and piroxicam.
    Xiong H; Liu G; Xiao J; Han Y; Liu T; Wan J; Yang J; Ding J; Dong X
    Eur J Dermatol; 2020 Oct; 30(5):620-621. PubMed ID: 33185537
    [No Abstract]   [Full Text] [Related]  

  • 9. Mixed signals: toxic epidermal necrolysis.
    Villano JH; Lovell EO
    Am J Med; 2015 Mar; 128(3):254-6. PubMed ID: 25460525
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous adverse drug reactions: an 8-year retrospective study on hospitalized patients in Southern China.
    Wang F; Li Y; Mo Y; Shen C; Yang L; Zhang X
    Indian J Dermatol Venereol Leprol; 2012; 78(4):488-90. PubMed ID: 22772622
    [No Abstract]   [Full Text] [Related]  

  • 11. A case of toxic epidermal necrolysis induced by allopurinol with human herpesvirus-6 reactivation.
    Watanabe Y; Matsukura S; Isoda Y; Morita A; Aihara M; Kambara T
    Acta Derm Venereol; 2013 Nov; 93(6):731-2. PubMed ID: 23604033
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence of Stevens-Johnson syndrome following combination drug use of allopurinol, carbamazepine and phenytoin in Taiwan: A case-control study.
    Syu FK; Pan HY; Chuang PC; Huang YS; Cheng CY; Cheng FJ
    J Dermatol; 2018 Sep; 45(9):1080-1087. PubMed ID: 29963717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Lee HY; Pang SM; Thamotharampillai T
    J Am Acad Dermatol; 2008 Aug; 59(2):352-3. PubMed ID: 18638633
    [No Abstract]   [Full Text] [Related]  

  • 14. Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective descriptive study.
    Carrasquillo OY; Santiago-Vazquez M; Cardona R; Cruz-Manzano M; Figueroa LD
    Int J Dermatol; 2019 Nov; 58(11):1293-1299. PubMed ID: 31166019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxic epidermal necrolysis (Lyell syndrome) in 77 elderly patients.
    Bastuji-Garin S; Zahedi M; Guillaume JC; Roujeau JC
    Age Ageing; 1993 Nov; 22(6):450-6. PubMed ID: 8310891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States.
    Lu N; Rai SK; Terkeltaub R; Kim SC; Menendez ME; Choi HK
    Semin Arthritis Rheum; 2016 Oct; 46(2):253-258. PubMed ID: 27217070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Febuxostat (Adenuric). Toxic epidermal necrolysis and severe hypersensitivity reactions added to the EU SPC.
    Prescrire Int; 2015 Jun; 24(161):153. PubMed ID: 26436167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe cutaneous adverse reactions in a local hospital setting: a 5-year retrospective study.
    Su P; Aw CW
    Int J Dermatol; 2014 Nov; 53(11):1339-45. PubMed ID: 25070588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stevens-Johnson syndrome and toxic epidermal necrolysis - retrospective review of cases in a high complexity hospital in Brazil.
    Medeiros MP; Carvalho CHC; Santi CG; Avancini J
    Int J Dermatol; 2020 Feb; 59(2):191-196. PubMed ID: 31173347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes.
    Tan SK; Tay YK
    Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.